Ethical debates in genetic engineering: U.S. scientists' attitudes on patenting, germ-line research, food labeling, and agri-biotech issues.
A 1995 survey of 1,257 scientists working in the field of recombinant DNA research indicates wide areas of agreement as well as some noteworthy divisions when it comes to such thorny questions as patenting, germ-line research, food labeling, and biodiversity. In general, the scientists surveyed approve of patenting living organisms that result from rDNA research, but vary significantly on what should be patentable. They advocate human germ-line therapy, yet have reservations about using it for any but serious diseases. They oppose mandatory labeling of biologically engineered food products, but understand that the public has a right to know and advocate openness. Finally, they favor development of threats to biodiversity and maintain that publicly funded researchers should be legally obligated to consider the potential environmental effects of their research. Some clear differences arise between scientists working in industry and those in academia and between men and women.
Rabino
I
I
SUNY-Empire STate College, New York, NY 10014, USA.
D022126:Access to Information; D001291:Attitude of Health Personnel; D004274:DNA, Recombinant; D017753:Ecosystem; D005260:Female; D005515:Food Labeling / Q000941:ethics; D005818:Genetic Engineering / Q000941:ethics*; D015316:Genetic Therapy / Q000941:ethics; D005854:Germ Cells; D006801:Humans; D008297:Male; D010330:Patents as Topic / Q000941:ethics; D030821:Plants, Genetically Modified; D017149:Private Sector; D012108:Research Personnel / Q000523:psychology*; D012109:Research Support as Topic; D011795:Surveys and Questionnaires; D014481:United States; D014495:Universities
D004274:DNA, Recombinant